title: The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
abstract: BACKGROUND
  Turoctocog alfa (NovoEight(®)) is a human recombinant coagulation factor VIII (rFVIII) for the treatment of patients with hemophilia A.
  
  
  OBJECTIVE
  To evaluate the pharmacokinetics of turoctocog alfa in all age groups across clinical trials.
  
  
  METHODS
  Data from previously treated patients with severe hemophilia A (FVIII activity level of ≤ 1%) with no history of FVIII inhibitors, in a non-bleeding state, were included. The pharmacokinetics were assessed following a wash-out period and a subsequent single intravenous 50 IU kg(-1) dose of turoctocog alfa. Blood was sampled during a 48-h period postdose. Standard pharmacokinetic (PK) parameters were estimated on the basis of plasma FVIII activity vs. time (PK profiles) with non-compartmental methods. Furthermore, a population PK analysis was conducted.
  
  
  RESULTS
  Data from 76 patients (aged 1-60 years) enrolled globally across six clinical trials were included, totaling 105 turoctocog alfa PK profiles. Single-dose PK results 3-6 months after the first dose of turoctocog alfa were comparable with the results obtained after the first dose. Similar PK characteristics were shown for different lots and strengths of the drug product. Overall, area under the plasma concentration (activity) curve from administration to infinity (AUC) and t1(/2) tended to increase with increasing age, with lower AUC and shorter t(1/2) being seen in children than in adolescents and adults. The PK profiles of turoctocog alfa and other commercially available plasma-derived FVIII and rFVIII products were similar in all age groups.
  
  
  CONCLUSIONS
  The PK characteristics of turoctocog alfa have been thoroughly studied, and shown to be consistent over time, reproducible between different lots and strengths of drug product, and similar to those observed for other FVIII products.
authors.affiliation: Hemophilia Center, La Paz University Hospital, Autonoma University, Madrid, Spain.
authors.forename: V
authors.initials: V
authors.lastname: Jiménez-Yuste
authors.forename: S
authors.initials: S
authors.lastname: Lejniece
authors.forename: R
authors.initials: R
authors.lastname: Klamroth
authors.forename: T
authors.initials: T
authors.lastname: Suzuki
authors.forename: E
authors.initials: E
authors.lastname: Santagostino
authors.forename: F A
authors.initials: FA
authors.lastname: Karim
authors.forename: T
authors.initials: T
authors.lastname: Saugstrup
authors.forename: J
authors.initials: J
authors.lastname: Møss
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D019540:Area Under Curve; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003029:Coagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D005169:Factor VIII / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D006207:Half-Life; D006467:Hemophilia A / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D012720:Severity of Illness Index; D013810:Therapeutic Equivalency; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D003029:Coagulants; C577506:recombinant factor VIII N8; D005169:Factor VIII
keywords: N8 recombinant factor VIII; blood coagulation disorders; hemophilia A; pharmacokinetics; turoctocog alfa